A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy

Alexander Haese1, Amy L. Tin2, Sigrid V. Carlsson3,4, Daniel D. Sjoberg2, Dirk Pehrke5, Thomas Steuber1, Hartwig Huland1, Markus Graefen1, Peter T. Scardino3, Thorsten Schlomm5, Andrew J. Vickers3, Hans Lilja3,6,7,8 and Guido Sauter9

BACKGROUND: A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease.

METHODS: The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4.

RESULTS: Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630–0.660) within GG 3 + 3, but not GG 3 + 4.

CONCLUSIONS: The 4Kscore can help guide the clinical decision whether additional risk assessment—such as confirmatory biopsy—is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation.

British Journal of Cancer (2020) 123:604–609; https://doi.org/10.1038/s41416-020-0914-7

BACKGROUND
Measurement of PSA in blood is the most common method to screen men for prostate cancer, and has been shown to reduce prostate cancer mortality. However, with its low specificity, most men with moderately elevated PSA do not have aggressive prostate cancer. Prostate biopsy is an invasive and uncomfortable diagnostic procedure associated with non-trivial risks of complications, including rectal haemorrhage, urinary tract infection, sepsis and hospitalisation.2,3 Moreover, the use of liberal criteria for biopsy are associated with the risk of identifying low-grade prostate cancer, which not only leads to the expense, inconvenience and anxiety of active surveillance, but often leads to overtreatment. Developing methods to improve the specificity and reduce the downstream harms of the PSA test is a major public health priority.

If low-to-intermediate-risk cancer (Gleason 3 + 3 and 3 + 4) is found on biopsy, the urologist faces challenging clinical decisions: (i) for those with Gleason 3 + 3, whether or not to perform a confirmatory biopsy or other risk assessment before recommending active surveillance,4,5 and (ii) for those with Gleason 3 + 4, whether or not to recommend curative treatment—surgery or radiation.

Prostate biopsy involves sampling the prostate and may underestimate disease severity. Approximately 30–40% of men with Gleason 3 + 3 on initial biopsy will have higher-grade cancer in the prostatectomy specimen.6–8 More accurate assessment of the nature of the cancer would increase both physician and patient confidence in the safety of active surveillance, or indications for immediate treatment.9,10

A statistical model based on a panel of 4K markers in blood—total, free, intact PSA and hK2, commercialised by OPKO Health Inc. (Miami, FL, USA) as the 4Kscore test can accurately predict Gleason 3 + 4 or higher prostate cancer on biopsy.11–14 The 4Kscore has also been shown to predict prostate cancer death in men followed for many years without screening.15,16 This suggests that the 4Kscore might aid risk stratification in patients with
low- and intermediate-risk cancer on biopsy. Our objective was to assess the ability of the 4Kscore to predict adverse pathology at prostatectomy—the gold standard for accurate histological diagnosis—and BCR, with a focus on men diagnosed with Gleason 3 + 3 or 3 + 4 prostate cancer at biopsy.

METHODS

Study design

This retrospective study included 2330 men with localised prostate cancer undergoing radical prostatectomy at Martiniklinik in Hamburg, Germany, a tertiary referral centre, between 2002 and 2010. All biopsies were 10–12-core transrectal ultrasound-guided biopsy using a standard template, with biopsy and pathological evaluation conducted at the Martini-Klinik. Kallikrein markers were measured in preoperative blood cryopreserved at −80°C. The rate of active surveillance at the time was very low, with almost all patients treated shortly after diagnosis. We excluded patients with missing pathology data at prostatectomy (n = 22), missing kallikrein measurements (n = 5) and suspected non-specific analytical interference in kallikrein measurements (n = 3).

Test methods

Sample aliquots were shipped to Dr. Lilja’s laboratory at Lund University in Malmö, Sweden for measurements of kallikrein levels conducted in 2016–2017 blind to outcome. Total and free PSA levels were measured using the AutoDelphi 1235 automatic immunoassay system using the dual-label DELFIA Prostate total/free PSA-Assay (Perkin-Elmer, Turku, Finland) calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards. Intact PSA and hK2 were measured with F(ab’2)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously.17,18 To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously. To reduce interobserver variability of pathologic specimen, all Gleason Grade were measured with F(ab)2 fragments of the monoclonal capture antibodies to reduce the frequency of non-specific assay interference, as described in detail previously.
Gleason 3 + 3 patients and smaller and less consistent benefit in biopsy Gleason 3 + 4 disease (Table 2 and Supplementary Table 7a–7d). Decision-curve analysis illustrated the improvement in net benefit of the 4Kscore in appropriate ranges for a decision threshold of 5–20% for biopsy Gleason 3 + 3, and to a lesser extent, 20–60% for biopsy Gleason 3 + 4 (Fig. 1a, b). To better illustrate its clinical relevance, Fig. 2 displays the risk of adverse pathology by 4Kscore for men with biopsy Gleason 3 + 3 or 3 + 4, highlighting the relevance of the 4Kscore for decisions about the confirmatory biopsy and definitive treatment, respectively. The clinical performance of proceeding with a confirmatory biopsy among biopsy Gleason 3 + 3 men at various illustrative cut points is shown in Supplementary Table 8. For example, performing a confirmatory biopsy in men with a clinical + 4Kscore risk greater than 10% in 10,000 men would reduce the number of biopsies by 3086. Of these men avoiding confirmatory biopsy, 195/40 would have adverse pathology with/without ECE.

Among the 2064 patients with available BCR data, 395 men experienced BCR. The median follow-up time for those without BCR was 7.9 years (IQR 6.0, 9.1). The rate of salvage treatment within 1 year after surgery was 1.3% (95% CI 0.9%, 1.9%). Higher 4Kscore was associated with BCR on univariable analysis (HR 1.44; 95% CI 1.34, 1.54, p < 0.0001) and multivariable analysis after adjusting for preoperative clinical factors (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). The association between 4Kscore and BCR was not significant after adjusting for post-operative variables (HR 1.00; 95% CI 0.90, 1.10; p = 0.9). Among men with biopsy Gleason 3 + 3 or 3 + 4 cancer, after adjusting for the preoperative nomogram, the 4Kscore was statistically significantly associated with BCR in men with biopsy Gleason 3 + 3 (HR 1.33; 95% CI 1.17, 1.52; p < 0.0001) but not in Gleason 3 + 4 (HR 1.09; 95% CI 0.92, 1.30; p = 0.3) (Table 3). Adding 4Kscore to the clinical model improved the prediction of BCR (C-index 0.630–0.660) within biopsy Gleason 3 + 3, but did not increase the C-index (0.620) among men with biopsy Gleason 3 + 4.

**DISCUSSION**

We assessed whether the 4K panel (commercialised by OPKO Health Inc. as the 4Kscore test), helpful in detecting the presence of high-grade cancer within the prostate before a biopsy, could be expanded to help clinicians better predict the presence of adverse pathology within the prostate in men with biopsy grade 3 + 3 or 3 + 4 cancers. Such a tool could substantially improve decision-making by clinicians and patients with the decision of whether to have additional testing, such as confirmatory biopsy, prior to active surveillance (among men with biopsy grade 3 + 3 cancers), or to start active surveillance or have immediate radical surgery (among men with biopsy grade 3 + 4 cancers). We found that 4Kscore was strongly associated with both adverse pathology and BCR among men with biopsy Gleason 3 + 3, and improved the clinical utility of preoperative risk models across an appropriate range of risk thresholds. However, 4Kscore does not improve the value of post-operative risk models and, therefore, does not appear useful for counselling men after prostatectomy regarding the likelihood of recurrence. These findings support the use of the 4Kscore for biopsy decision-making as they suggest that, where grade 3 + 3 or 3 + 4 is to be found, the 4Kscore obtained at the time of biopsy decision-making could be used to make subsequent decisions about clinical management.

Our findings are supported by several prior studies. We have previously demonstrated that free PSA and hK2 enhance the predictive accuracy of clinical models predicting adverse pathology and BCR. In a cohort of 392 men from the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer treated with radical prostatectomy, predictions based on levels of four kallikrein markers accurately distinguished between pathologically insignificant and aggressive disease (addition of the kallikrein panel increased the AUC to 0.84, p < 0.0005). In a prospective multi-institutional study comprising 1312 men treated with radical prostatectomy at 26 sites in the United States, Punnen et al. showed that the 4Kscore was associated with Gleason score and ECE in the prostatectomy specimen. However, the 4Kscore was not found to improve the prediction of aggressive cancers when added to clinical prediction models, possibly due to small sample size. Regarding the utility of the 4Kscore in the active surveillance setting, Lin et al. prospectively evaluated 718 men enrolled in the multi-institutional Canary PASS trial, demonstrating that 4Kscore improved predictions of high-grade prostate cancer at confirmatory biopsy, but did not add substantive predictive value at subsequent surveillance biopsies. Similar findings were seen in a Spanish study of 137 men on active surveillance, where 4Kscore risk was associated with reclassification at confirmatory biopsy. Among men with 4Kscore below 7.5%, reclassification to Gleason 3 + 4 was missed in 2 men (6%) with no reclassification to Gleason 4 + 3.

With 2330 patients, the present study is the largest series evaluating the role of the 4Kscore in predicting adverse pathology...
Table 2. Association between 4Kscore and adverse pathology on multivariable analysis, with optimism-corrected area under the curve (AUC)*.

| Cohort analysis† | Sample size | Odds ratiob | 95% CIb | p valuec | Clinical | Clinical + 4Kscore | Only 4Kscore |
|------------------|-------------|-------------|---------|---------|----------|-------------------|-------------|
| Primary analysis† |             |             |         |         |          |                   |             |
| All biopsy Gleason Grades | 2330 | 1.49 | 1.32,1.67 | < 0.0001 | –        | –                 | –           |
| Biopsy Gleason Grade 3 + 3 | 1484 | 1.73 | 1.47,2.04 | < 0.0001 | 0.672    | 0.718             | 0.717       |
| Biopsy Gleason Grade 3 + 4 | 524  | 1.32 | 1.10,1.59 | < 0.0001 | 0.644    | 0.659             | 0.652       |
| Sensitivity analysis† |             |             |         |         |          |                   |             |
| All biopsy Gleason Grades | 1359 | 1.43 | 1.23,1.67 | < 0.0001 | –        | –                 | –           |
| Biopsy Gleason Grade 3 + 3 | 789  | 1.55 | 1.27,1.89 | < 0.0001 | 0.651    | 0.724             | 0.724       |
| Biopsy Gleason Grade 3 + 4 | 356  | 1.20 | 0.97,1.48 | < 0.10   | 0.677    | 0.686             | 0.632       |
| Sensitivity analysis† |             |             |         |         |          |                   |             |
| All biopsy Gleason Grades | 1359 | 1.29 | 1.10,1.52 | < 0.0001 | –        | –                 | –           |
| Biopsy Gleason Grade 3 + 3 | 789  | 1.64 | 1.33,2.03 | < 0.0001 | 0.625    | 0.753             | 0.760       |
| Biopsy Gleason Grade 3 + 4 | 356  | 1.25 | 0.98,1.60 | < 0.073  | 0.616    | 0.642             | 0.636       |

* AUC for models in all biopsy Gleason Grades was not calculated since blood sample available prior to surgery was not representative of the distribution of all radical prostatectomy patients at Martini-Klinik.
† Odds ratios are for a one-point increase when taking the logit of the 4Kscore.
‡ Definition of adverse pathology includes ECE, and the clinical model also includes the number of positive cores on biopsy, and tumour length on biopsy.
§ As per primary analysis, except that the clinical model also includes the number of positive cores on biopsy, and tumour length on biopsy.
¶ As per primary analysis, except that the definition of adverse pathology excludes ECE, and the clinical model also includes the number of positive cores on biopsy, and tumour length on biopsy.

Fig. 1 Decision curve analysis based on Gleason Grade. The decision curve analysis compares the net benefit of the clinical + 4Kscore model (blue or dark grey dashed line), clinical-model (green or light grey dashed line), treat-all (orange or light grey solid line), and treat-none (horizontal red or grey solid line) strategies among biopsy (a) Gleason Grade 3 + 3 patients and (b) Gleason Grade 3 + 4 patients.

at radical prostatectomy. It is also the first study to evaluate the utility of the 4Kscore for the endpoint of BCR.

One limitation of this study is that detailed biopsy pathology with the number of positive cores and millimetres of cancerous tissue was available for 58% of the cohort. Moreover, the percentage of Gleason 4 was lacking in most Gleason 3 + 4 biopsies. As quantitative Gleason grading provides substantial prognostic information in Gleason 3 + 4 carcinomas, the impact of the 4Kscore may be dampened. However, the findings from sensitivity analyses that included detailed biopsy pathology data were similar to the main findings. This suggests that the 4Kscore adds important information about the risk of adverse pathology above and beyond that contained in detailed reporting of biopsy pathology, such as the number of cores and tumour length, which is not routinely reported by pathologists.

A second possible limitation is that our study was restricted to a single centre. Our findings on Gleason 3 + 3, related to confirmatory biopsy, replicate those of a prior study, our findings on treatment decision-making in Gleason 3 + 4 disease require further investigation. Finally, our cohort and results are in the pre-MRI era, and the association between 4Kscore, outcomes and MRI is not fully established and requires further research.

CONCLUSION

The 4Kscore strongly predicts adverse pathology and BCR in men with low-grade cancer on biopsy. In practice, the 4Kscore, along with additional tests such as MRI, could assist physicians and their patients in making the critical clinical decision for Gleason 3 + 3 cancers: whether to engage in additional risk assessment, such as a confirmatory biopsy, before initiating active surveillance. Evidence that the 4Kscore improves decision-making in biopsy Gleason 3 + 4 cancer (e.g. active surveillance vs definitive treatment) is less strong, but worthy of further study, especially in cohorts with low volume of Gleason pattern 4.
ACKNOWLEDGEMENTS
Not applicable.

AUTHOR CONTRIBUTIONS
A.H. conceived the idea, acquired the data and revised the paper. A.T. analysed and interpreted the data, carried out the statistical analysis, drafted and revised the paper. S.C. interpreted the data and drafted the paper. D.S. interpreted the results and revised the paper. D.P. acquired data and revised the paper. T. Steuber conceived the idea and revised the paper. H.H. conceived the idea and revised the paper. M.G. conceived the idea and revised the paper. P.S. conceived the idea and revised the paper. T. Schlomm conceived the idea and revised the paper. A.V. conceived and designed the idea, analysed and interpreted the data and revised the paper. H.L. conceived and designed the idea, interpreted the data and revised the paper. G.S. conceived the idea and revised the paper.

ADDITIONAL INFORMATION
Ethics approval and consent to participate Ethical approval was obtained from the MSKCC IRB. Consent was not sought from participants for this retrospective biomarker study as this was waived by the IRB. The study was performed in accordance with the Declaration of Helsinki.

Consent to publish Not applicable.

Data availability The data sets analysed for this study will be made available to researchers on reasonable request to the corresponding author.

Competing interests Hans Lilja holds patents on assays for free PSA, intact PSA and hK2. Andrew Vickers, Hans Lilja, and Peter Scardino are named on a patent for a statistical method to detect prostate cancer (the 4KScore test) that has been commercialised by OPKO Health. Andrew Vickers, Hans Lilja and Peter Scardino receive royalties from sales of the test. Hans Lilja and Peter Scardino have stock, and Andrew Vickers has stock options in OPKO Health. Sigrid Carlson has received a lecture honorarium and travel support from Astellas Pharma (unrelated to the current study). The other authors declare no other competing interests.

Funding information This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], a SPORE grant in Prostate Cancer to Dr. H. Scher [P50 CA092629], the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation. This work was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Program in the United Kingdom, the Swedish Cancer Society (CAN 2017/559), the Swedish Research Council (VR-MH project no. 2016-02974) and General Hospital in Malmö Foundation for Combating Cancer.

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-0914-7.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V. et al. Screening and prostate cancer mortality: results of the European
